⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for raynaud's phenomenon secondary to systemic sclerosis

Every month we try and update this database with for raynaud's phenomenon secondary to systemic sclerosis cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Study of Acute Peripheral Vascular Effects, Safety and Tolerability in Subjects With Raynaud's Phenomenon Secondary to Systemic SclerosisNCT02228850
Raynaud's Pheno...
Alprostadil
Placebo
18 Years - 79 YearsNexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)
Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3)NCT04040322
Raynaud's Pheno...
Placebo IV infu...
Iloprost Inject...
18 Years - Eicos Sciences, Inc.
Effects of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic SclerosisNCT02260557
Raynaud's Pheno...
Selexipag
Placebo
18 Years - Actelion
Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3)NCT04040322
Raynaud's Pheno...
Placebo IV infu...
Iloprost Inject...
18 Years - Eicos Sciences, Inc.
A Study to Assess the Effect of Oral Temanogrel on Digital Blood Flow in Adult Participants With Raynaud's Phenomenon Secondary to Systemic SclerosisNCT04915950
Raynaud's Pheno...
Temanogrel
Placebo
18 Years - 75 YearsPfizer
Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3)NCT04040322
Raynaud's Pheno...
Placebo IV infu...
Iloprost Inject...
18 Years - Eicos Sciences, Inc.
Study of Acute Peripheral Vascular Effects, Safety and Tolerability in Subjects With Raynaud's Phenomenon Secondary to Systemic SclerosisNCT02228850
Raynaud's Pheno...
Alprostadil
Placebo
18 Years - 79 YearsNexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)
Effects of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic SclerosisNCT02260557
Raynaud's Pheno...
Selexipag
Placebo
18 Years - Actelion
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: